Pyxis Oncology, Inc. (PYXS) NASDAQ

Currency In USD

Pyxis Oncology, Inc.

Address

35 Cambridgepark Drive

Boston, MA 02140

United States of America (the)

Phone

617 221 9059

Website

https://www.pyxisoncology.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

October 08, 2021

Key Executives

Name	Title	Pay	Year Born
Thomas Civik	Interim CEO & Director	47,500	1969
Jitendra Wadhane	Chief Accounting Officer, Senior Vice President of Finance, Corporate Controller & Principal Financial Officer	559,050	1981
Shui He	Head of Biometrics	0	N/A
Donna Regalado	Head of Human Resources	0	N/A
Balu N. Balasubramanian	Interim Chief Technology Officer	0	N/A
Charles T. Gombar	Senior Vice President of Portfolio & Program Management	0	N/A
Chris Cohen	Head of Drug Safety & Pharmacovigilance	0	N/A
Hongwei Wang	Head of ADC Development & Clinical Strategy	0	N/A
Jan Pinkas	Chief Scientific Officer	0	1969
Michael Bui	Senior Vice President of Global Regulatory Affairs	0	N/A
Supriya Roth	Head of Commercial Development	0	N/A
Alex Kane	Senior Vice President of Investor Relations & Capital Markets	0	N/A
Marsha Crochiere	Head of Translational Medicine & Research	0	N/A

Description

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.